Oligonucleotides as novel linkers for ADCs
Updated time: 2023-11-03 14:18:25
Oligonucleotides as novel linkers for ADCs
Docket Number
11A-1090121
Announcement Date
2020-12-03
IP Status
TW I817107
Abstract
Using strand-pairing between oligonucleotides as a novel linker for antibody-drug conjugates. Complementary strands with toxic payload can be combine with antibody-oligo conjugates in a modularized way to be selectively delivered to cancer cells. Our technology has the potential to become a next-generation platform for targeted cancer therapy.
Technological Advantages
- High water solubility of the oligonucleotides can mitigate the issue of aggregation stemming from highly hydrophobic payloads. Compared to traditional covalent linkages such as click chemistry, the presence of hydrophobic moieties on the linker often brings undesirable properties.
- Complementary strands with different payloads and antibody-oligo conjugates with different antigen specificities can be developed separately for modularized preparation of targeted therapeutics.
Applications of Technology
- The treatment and diagnosis of cancer. Creation of molecules with novel properties by attaching other functional payloads to the antibody.
Inventor
Andrew H. –J. Wang、Cheng-Chung Lee、Nai-Shu Hsu、Wen-Chih Kuo
Contact person
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office
Download Files

Oligonucleotides as novel linkers for ADCs